Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Intriguing Relationships Between Cancer and Systemic Sclerosis: Role of the Immune System and Other Contributors.

Maria ATJ, Partouche L, Goulabchand R, Rivière S, Rozier P, Bourgier C, Le Quellec A, Morel J, Noël D, Guilpain P.

Front Immunol. 2019 Jan 10;9:3112. doi: 10.3389/fimmu.2018.03112. eCollection 2018. Review.

2.

iNOS Activity Is Required for the Therapeutic Effect of Mesenchymal Stem Cells in Experimental Systemic Sclerosis.

Maria ATJ, Rozier P, Fonteneau G, Sutra T, Maumus M, Toupet K, Cristol JP, Jorgensen C, Guilpain P, Noël D.

Front Immunol. 2018 Dec 21;9:3056. doi: 10.3389/fimmu.2018.03056. eCollection 2018.

3.

Mesenchymal Stem Cells in Systemic Sclerosis: Allogenic or Autologous Approaches for Therapeutic Use?

Rozier P, Maria A, Goulabchand R, Jorgensen C, Guilpain P, Noël D.

Front Immunol. 2018 Dec 14;9:2938. doi: 10.3389/fimmu.2018.02938. eCollection 2018. Review.

4.

Fibrosis Development in HOCl-Induced Systemic Sclerosis: A Multistage Process Hampered by Mesenchymal Stem Cells.

Maria ATJ, Toupet K, Maumus M, Rozier P, Vozenin MC, Le Quellec A, Jorgensen C, Noël D, Guilpain P.

Front Immunol. 2018 Nov 5;9:2571. doi: 10.3389/fimmu.2018.02571. eCollection 2018.

5.

Impact of MPO-ANCA-mediated oxidative imbalance on renal vasculitis.

Hilhorst M, Maria AT, Kavian N, Batteux F, Borderie D, Le Quellec A, van Paassen P, Guilpain P.

Am J Physiol Renal Physiol. 2018 Dec 1;315(6):F1769-F1776. doi: 10.1152/ajprenal.00111.2018. Epub 2018 Sep 12.

PMID:
30207165
6.

Therapeutic innovation in adult-onset Still's disease (and other rare inflammatory disorders): how to secure evidence-based medicine?

Guilpain P, Le Quellec A, Maria ATJ.

Ann Rheum Dis. 2018 Dec;77(12):1699-1701. doi: 10.1136/annrheumdis-2018-213106. Epub 2018 Jun 2. No abstract available.

PMID:
29860231
7.

Serum-Mediated Oxidative Stress from Systemic Sclerosis Patients Affects Mesenchymal Stem Cell Function.

Fonteneau G, Bony C, Goulabchand R, Maria ATJ, Le Quellec A, Rivière S, Jorgensen C, Guilpain P, Noël D.

Front Immunol. 2017 Sep 1;8:988. doi: 10.3389/fimmu.2017.00988. eCollection 2017.

8.

Reply.

Maria AT, Jorgensen C, Le Quellec A, Noël D, Guilpain P.

Arthritis Rheumatol. 2016 Sep;68(9):2348-50. doi: 10.1002/art.39756. No abstract available.

9.

Adipose-Derived Mesenchymal Stem Cells in Autoimmune Disorders: State of the Art and Perspectives for Systemic Sclerosis.

Maria AT, Maumus M, Le Quellec A, Jorgensen C, Noël D, Guilpain P.

Clin Rev Allergy Immunol. 2017 Apr;52(2):234-259. doi: 10.1007/s12016-016-8552-9. Review.

10.

Human adipose mesenchymal stem cells as potent anti-fibrosis therapy for systemic sclerosis.

Maria AT, Toupet K, Maumus M, Fonteneau G, Le Quellec A, Jorgensen C, Guilpain P, Noël D.

J Autoimmun. 2016 Jun;70:31-9. doi: 10.1016/j.jaut.2016.03.013. Epub 2016 Apr 1.

PMID:
27052182
11.

Antifibrotic, Antioxidant, and Immunomodulatory Effects of Mesenchymal Stem Cells in HOCl-Induced Systemic Sclerosis.

Maria AT, Toupet K, Bony C, Pirot N, Vozenin MC, Petit B, Roger P, Batteux F, Le Quellec A, Jorgensen C, Noël D, Guilpain P.

Arthritis Rheumatol. 2016 Apr;68(4):1013-25. doi: 10.1002/art.39477.

12.

Adult onset Still's disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions.

Maria AT, Le Quellec A, Jorgensen C, Touitou I, Rivière S, Guilpain P.

Autoimmun Rev. 2014 Nov;13(11):1149-59. doi: 10.1016/j.autrev.2014.08.032. Epub 2014 Aug 27. Review.

PMID:
25183244
13.

Asymptomatic bilateral pulmonary embolism in Churg-Strauss syndrome.

Maria A, Guilpain P, Forestier A, Delhom E, Schiffman A, Rivière S, Van Kien AK, Leray-Moragues H, Serre I, Vincent T, Eliaou JF, Le Quellec A.

Eur Respir Rev. 2012 Mar 1;21(123):75-7. doi: 10.1183/09059180.00007911. No abstract available.

Supplemental Content

Loading ...
Support Center